biotech / news / / The Boston Globe
Eli Lilly & Co. agrees to buy Kelonia Therapeutics for as much as $7 billion.
Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion.
KEY POINTS
- Kelonia's lead drug uses in vivo CAR-T technology for multiple myeloma patients.
- The novel therapy does not require immune cell removal or pre-infusion chemotherapy.
- Kelonia is enrolling patients in an early-stage trial for this new treatment.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →